

AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development

03 December 2025 | News

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules

As drug developers face increasing pressure to lower prices and accelerate time to market, global biopharmaceutical contract development and manufacturing organization AGC Biologics is expanding its Cell Line Development Center of Excellence by partnering with ATUM to integrate the Leap-In Transposase[®] expression platform within its offerings. This partnership provides drug developers with technology designed to increase yields and significantly shorten the path to clinical trials, directly addressing the market's need for speed and efficiency.

Implementing this technology in process development and manufacturing can reduce timelines by three months on average.

With ATUM's modern transposase-based platform now available through AGC Biologics, the CDMO offers a range of cell line development options to meet diverse customer needs, from complex molecules requiring rapid development to more straightforward projects where timelines are less critical. This partnership brings proven cell engineering expertise to develop the next generation of antibodies strong enough to kill cancerous tumors, fight viral infections, and provide precision immunosuppression for autoimmune conditions.

ATUM's Leap-In technology is a transposase-based platform that stably integrates DNA into a host cell's genome, enabling the rapid development of highly productive and genetically stable cell lines. Implementing this technology in process development and manufacturing can reduce timelines by three months on average. The high-quality stable pools generated by the technology are highly predictive of final clonal line titers, allowing critical process development and analytical work to begin earlier, reducing risk and further shortening the project timeline.

This new offering builds on AGC Biologics' in-house CHEF1[®] Expression Technology, which has supported the development of five commercially approved products. The addition of the ATUM platform creates a comprehensive suite of cell line development services, allowing AGC Biologics to offer customized solutions that align with a customer's specific molecule, budget, and timeline. These services are available across AGC Biologics' global network, with sites in the United States, Europe, and Asia.